desogestrel
ApprovedSmall molecule
desogestrel is one of 55 small molecule programs targeting Uterine leiomyoma. It is currently in Approved.
3
Indications
9
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
199 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Orilissa
AbbViePhase 3
Lupron
AbbViePhase 3
Revia
TevaPhase 3
Firmagon
FerringPhase 3
desogestrel
MMahidol University
Approved
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
EE20/DRSP(BAY86-5300)
BayerPhase 3
Triptorelin Embonate
IpsenPhase 3
Indole-3-Carbinol
UUniversity of Kansas Medical Center
Phase 3
Add-Back
KKissei Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Uterine leiomyoma1 trial
Treatment1 trial
Hypoventilation1 trial
Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome
Terminated·—·Phase 2·NCT01500473·1 enrolled
4 more indications
Abnormal Uterine Bleeding1 trial
Abnormal Uterine Bleeding and Progestin-only Contraceptives
Completed·—··NCT03398811·390 enrolled
Preoperative1 trial
Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 2/3·NCT04941833·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for desogestrel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMahidol University